Source: Mail & Guardian — 23 July 2026
An opinion piece arguing that South Africa’s semaglutide controversy is ultimately about whether the public still trusts the institutions meant to protect their health, drawing on SAHPRA, local obesity data and the Novo Nordisk vs iDexis legal dispute. It frames affordability and safety as symptoms of a deeper institutional trust deficit.